FDA’s Power Morcellation Containment System Guidance Doc Finalized
Executive Summary
The US FDA has finalized a guidance document that details performance assessment standards for power morcellation containment systems. The class II devices have been an object of special scrutiny since the agency learned that power morcellation could spread cancerous tissue throughout the body.
You may also be interested in...
Morcellation Use Drops After FDA Warning
Surgeons are opting for alternate hysterectomy methods since the FDA warned power morcellation may spread cancerous cells through the body.
Morcellation Containment System Guidance Stresses Leak Detection, Prevention
A new US FDA draft guidance explains what the agency wants to see in submissions for the devices, which are used to contain potentially cancerous tissue during laparoscopic surgery. Strength, permeability and leakage testing are all key considerations.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.